Objective  To evaluate the efficacy and safety of polyene phosphatidylcholine injection in the treatment of liver disease.

Methods  Pubmed, Embase, The Cochrane Library, ClinicalTrial.gov, CNKI, SinoMed, VIP, and WanFang Data were electronically searched to collect randomized controlled trials (RCTs) of polyene phosphatidylcholine injection in the treatment of liver disease from inception to December 31st, 2022. Two researchers independently screened literature, extracted data and assessed the risk of bias of the included studies. The Meta-analysis was performed using Stata 17.0 software.

Results  A total of 10 RCTs were included, including 809 patients. Meta-analysis showed that the effective rate in the polyene phosphatidylcholine injection group was higher than that in the control group (RR=1.12, 95%CI 1.04 to 1.20, P=0.003 8). Compared with the control group, polyene phosphatidylcholine injection could decrease ALT level (MD=-18.92 U/L, 95%CI -27.75 to -10.09, P< 0.001), AST level (MD=-31.19 U/L, 95%CI -46.27 to -16.11, P=0.000 1), TBiL level (MD=-7.31 μmol/L, 95%CI -10.75 to -3.88, P<0.001), and GGT levels (MD=-48.93 U/L, 95%CI -54.64 to -43.21, P<0.001). Only one study reported mild adverse events, and six studies reported no severe adverse events in patients.

Conclusion   Current evidence shows that polyene phosphatidylcholine injection in the treatment of alcoholic liver disease can increase the effective rate, improve the levels of liver function indicators (ALT, AST, TBiL, and GGT), and has less adverse events. Due to the limited number and quality of included studies, the above conclusions need to be verified by more high-quality studies.

1.高潇雪, 刘立新. 酒精性肝病流行病学及发病机制研究进展[J]. 中华消化病与影像杂志(电子版), 2016, 6(2): 62-65. [Gao XX, Liu LX. Progress in the epidemiology and pathogenesis of alcoholic liver diseases[J]. Chinese Journal of Digestive Diseases and Imaging electronic edition, 2016, 6(2): 62-65.] DOI: 10.3877/cma.j.issn.2095-2015.2016.02.004.

2.中华医学会肝病学分会脂肪肝和酒精性肝病学组. 酒精性肝病诊疗指南[J]. 中国肝脏病杂志(电子版), 2010, 2(4): 49-53.] DOI: 10.3969/j.issn.1008-7125. 2010.10.011.

3.厉有名. 酒精性肝病的流行病学特点[J]. 实用肝脏病杂志, 2012, 15(3): 180-182. [Li YM. Epidemiological characteristics of alcoholic liver disease[J]. Journal of Practical Liver Diseases, 2012, 15(3): 180-182.] DOI: 10.3969/j.issn.1672-5069.2012.03.002.

4.全国酒精性肝病调查协作组, 迟宝荣. 全国酒精性肝病的多中心调查分析[J]. 中华消化杂志, 2007, 27(4): 231-234. DOI: 10.3760/j.issn:0254-1432.2007.04.005.

5.王涛, 陈东风. 多烯磷脂酰胆碱通过过氧化物酶体增殖物激活爱体α/肉碱棕榈酰基转移酶1A通路影响肝细胞脂肪变性[J]. 中华肝脏病杂志, 2016, 24(4): 291-296. [Wang T, Chen DF. Effect of polyene phosphatidyl choline on hepatocvte steatosis via PPARα/CPT-1A pathway[J]. Chinese Journal of Liver Diseases, 2016, 24(4): 291-296.] DOI: 10.3760/cma.j.issn.1007-3418.2016.04.010.

6.徐京杭. 多烯磷脂酰胆碱在肝病临床应用的专家共识[J]. 临床消化病杂志, 2017, 29(6): 331-338. [Xu JH. Experts consensus on the treatment with polyenphosphatidylcholine in patients with liver diseases[J]. Journal of Clinical Gastroenterology, 2017, 29(6): 331-338.] DOI: CNKI:SUN:ZSGR. 0.2017-04-001.

7.胡国平, 刘凯, 赵连三. 多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J]. 肝脏, 2005, 10(1): 5-7. [Hu GP, Liu K, Zhao LX. Polyunsaturated phosphatidylcholine (Essentiale) for alcoholic/fatty liver: A systematic review[J]. Liver, 2005, 10(1): 5-7.] DOI: 10.3969/j.issn.1008-1704.2005.01.003.

8.Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials[J]. BMJ, 2011, 343: d5928. DOI: 10.1136/bmj.d5928.

9.金玉坤, 罗雁, 陆伟. 易善复治疗酒精性脂肪肝的临床研究[J]. 实用肝脏病杂志, 2008, 11(2): 104-105. [Jin YK, Luo Y, Lu W. Clinical study on the treatment of alcoholic fatty liver with Essentiale[J]. Journal of Practical Liver Diseases, 2008, 11(2): 104-105.] DOI: 10.3969/j.issn. 1672-5069.2008.02.012.

10.王宛明. 多烯磷脂酰胆碱治疗酒精性肝病32例临床观察[J]. 山东医药, 2008, 48(19): 21. [Wang WM. Clinical observation of 32 cases of alcoholic liver disease treated with polyene phosphatidylcholine[J]. Shandong Medicine, 2008, 48(19): 21.] DOI: 10.3969/j.issn.1002-266X. 2008.19.071.

11.谢俊平, 陈创坤, 杜永龙. 多烯磷脂酰胆碱治疗乙醇性脂肪肝24例疗效观察[J]. 医学综述, 2009, 15(3): 469-470. [Xie JP, Chen CK, Du YL. Therapeutic effect of polyene phosphatidylcholines on 24 Cases with alcoholic fatty liver[J]. Medical Review, 2009, 15(3): 469-470.] DOI: 10.3969/j.issn.1006-2084.2009.03.050.

12.胡振斌, 官志杰, 周阳红, 等. 多烯磷脂酰胆碱联合血塞通治疗酒精性脂肪肝的临床观察[J]. 辽宁中医药大学学报, 2009, 11(7): 98-99. [Hu ZB, Guan ZJ, Zhou YH, et al. Clinical observation of polyene phosphatidylcholine combined with Xuesaitong in treatment of alcoholic fatty liver[J]. Journal of Liaoning University of Chinese Medicine, 2009, 11(7): 98-99.] DOI: CNKI:SUN:LZXB. 0.2009-07-056.

13.王晖, 姜齐宏, 但自力. 多烯磷脂酰胆碱联合苦参碱治疗酒精性肝病50例疗效观察[J]. 山东医药, 2009, 49(41): 93. [Wang H, Jiang QH, Dan ZL. Therapeutic effect of polyene phosphatidylcholine combined with matrine in the treatment of 50 cases of alcoholic liver disease[J]. Shandong Medicine, 2009, 49(41): 93.] DOI: 10.3969/j.issn.1002-266X.2009.41.052.

14.陈予. 腺苷蛋氨酸与多烯磷脂酰胆碱治疗酒精性肝硬化的疗效比较[J]. 胃肠病学和肝病学杂志, 2014, 23(8): 927-929. [Chen Y. Comparison of effects of S-adenosylmethionine and polyene phosphatidyl choline in the treatment of alcoholic cirrhosis[J]. Journal of Gastroenterology and Hepatology, 2014, 23(8): 927-929.] DOI: 10.3969/j.issn.1006-5709.2014.08.022.

15.曹智丽, 车建斌, 张文双, 等. 多烯磷脂酰胆碱联合丹参酮ⅡA磺酸钠注射液治疗酒精性肝硬化的临床观察[J]. 中国医药导报, 2016, 13(25): 55-58. [Cao ZL, Chen JB, Zhang WS, et al. Clinical observation on the treatment of alcoholic liver cirrhosis with the combination of polyene phosphatidyl choline and tanshinone IIA sul-fonate sodium injection[J]. China Medical Herald, 2016, 13(25): 55-58.] DOI: CNKI:SUN:YYCY.0.2016-25-015.

16.曹智丽, 张文双, 王维, 等. 还原型谷胱甘肽联合多烯磷脂酰胆碱治疗对酒精性肝病患者肝功能及肝纤维化指标的影响[J]. 广西医学, 2017, 39(3): 334-336. [Cao ZL, Zhang WS, Wang W, et al. Effect of reduced glutathione combined with polyene phosphatidylcholine on indicators of liver function and liver fibrosis in the treatment of patients with alcoholic liver disease[J]. Guangxi Medicine, 2017, 39(3): 334-336.] DOI: 10.11675/j.issn.0253-4304.2017.03.14.

17.张余黄, 殷鹏飞. 多烯磷脂酰胆碱联合还原型谷胱甘肽治疗酒精性肝炎效果观察[J]. 陕西医学杂志, 2019, 48(12): 1715-1717, 1745. [Zhang YH, Duan PF. Curative effect of polyene phosphatidyl choline combined with glutathione on alcoholic hepatitis[J]. Shaanxi Medical Journal, 2019, 48(12): 1715-1717, 1745.] DOI: CNKI:SUN:SXYZ.0.2019-12-038.

18.陈小芳, 徐惠明, 周明霞, 等. 多烯磷脂酰胆碱治疗酒精性肝病伴脂肪肝的疗效评价[J]. 中国组织工程研究, 2016, 20: 65-66. [Chen XF, Xu HM, Zhou MX, et al. Evaluation of fatty liver in alcoholic liver disease with multi-phosphatidylcholine[J]. Journal of Clinical Rehabilitative Tissue Engineering Research, 2016, 20: 65-66.] https://www.nstl.gov.cn/paper_detail.html?id=e089fe1472888e8047515af36122d25a.

19.罗兴献, 张颖, 于泽, 等. 多烯磷脂酰胆碱注射液用于治疗非酒精性脂肪性肝病的疗效和安全性Meta分析 [J]. 中国临床药理学杂志, 2021, 37(9): 1117-1120. [Luo XX, Zhang Y, Yu Z, et al. Meta analysis of the efficacy and safety of polyene phosphatidylcholine injection in the treatment of non-alcoholic fatty liver disease[J]. Chinese Journal of Clinical Pharmacology, 2021, 37(9): 1117-1120.] DOI: 10.13699/j.cnki.1001-6821.2021.09.022.

20.魏重操, 刘娜, 邢欣, 等. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪性肝病患者疗效和安全性Meta分析[J]. 实用肝脏病杂志, 2020, 23(1): 46-49. [Wei CX, Liu Na, Xing X, et al. Efficacy and safety ofpolyene phosphatidylcholine combined with metformin in the treatment of patients with non-alcoholic fatty liver disease: a Meta-analysis[J]. Journal of Practical Liver Diseases, 2020, 23(1): 46-49.] DOI: 10.3969/j.issn.1671-6450.2009.08.025.

21.丁莹. 多烯磷脂酰胆碱辅助改善妊娠期肝内胆汁淤积妊娠结局的Meta分析[J]. 临床合理用药杂志, 2019, 12(14): 16-18. [Ding Y. Meta-analysis of polyene phosphatidylcholine in improving pregnancy outcome of intrahepatic cholestasis during pregnancy[J]. Journal of Clinical Rational Drug Use, 2019, 12(14): 16-18.] DOI: 10.15887/j.cnki.13-1389/r.2019.14.007.

22.文晓玲, 张海浪. 多烯磷脂酰胆碱不良反应文献分析[J]. 中国药物警戒, 2020, 17(8): 526-530. [Wen XL, Zhang HL. Literature analysis of adverse reactions caused by polyene phosphatidyl choline[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 526-530.] DOI: 10. 19803/j.1672-8629.2020.08.16.